

Epcoritamab

Cat. No.:	HY-P99931
CAS No.:	2134641-34-0
Target:	CD3; CD20
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines ^[1] .
In Vitro	Epcoritamab (30 ng/mL) induces potent cytotoxicity in the presence of healthy donor peripheral blood mononuclear cells (PBMCs) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. van der Horst HJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. *Blood Cancer J.* 2021 Feb 18;11(2):38.

[2]. Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3×CD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. *J Clin Oncol.* 2023 Apr 20;41(12):2238-2247.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA